Urun Y, Utkan G, Altundag K, Arslan O, Onur H, Arslan U Y, Kocer M, Dogan I, Senler F C, Yalcin B, Demirkazik A, Akbulut H, Icli F
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
J BUON. 2012 Jul-Sep;17(3):457-60.
The role of genetic factors in the development of cancer is widely accepted. Data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. The aim of this study was to investigate the presence of a possible association between HER2 (+) breast cancer in Turkish women and ABO blood groups and Rh factor.
In 294 female patients with HER2 (+) breast cancer, ABO blood groups and Rh factor were examined. The relationship of blood groups with age, menopausal status, and family history of cancer, estrogen receptor (ER), progesterone receptor (PR) and HER2 status of these patients was evaluated. Blood groups distribution of 22,821 healthy blood donors was also assessed and compared with the patients' blood groups distribution.
The median patient age was 47 years (range 20-80) and 56% of the patients were premenopausal. ER and PR were positive in 50 and 60% of the patients, respectively. Overall, the ABO blood group distribution of the 294 HER2 (+) breast cancer patients was similar to that of the healthy blood donors (p=0.36). Likewise there was no correlation between blood type and ER, PR and menopausal status. Rh (-) patients had more frequent family cancer history and this difference was significant for patients with blood group B Rh (-) and O Rh (-) (p = 0.04).
In the present study we didn't find any relationship between HER2 status and ABO blood group and Rh factor. However, further studies with larger number of patients are needed to establish the role (if any) of blood groups in patients with breast cancer.
遗传因素在癌症发生发展中的作用已被广泛认可。关于ABO血型和Rh因子在乳腺癌中作用的数据尚无定论。本研究旨在调查土耳其女性HER2（+）乳腺癌与ABO血型及Rh因子之间是否存在可能的关联。
对294例HER2（+）乳腺癌女性患者进行ABO血型和Rh因子检测。评估这些患者的血型与年龄、绝经状态、癌症家族史、雌激素受体（ER）、孕激素受体（PR）及HER2状态之间的关系。还评估了22821名健康献血者的血型分布，并与患者的血型分布进行比较。
患者的中位年龄为47岁（范围20 - 80岁），56%的患者处于绝经前。ER和PR分别在50%和60%的患者中呈阳性。总体而言，294例HER2（+）乳腺癌患者的ABO血型分布与健康献血者相似（p = 0.36）。同样，血型与ER、PR及绝经状态之间无相关性。Rh（-）患者的家族癌症病史更为常见，血型为B Rh（-）和O Rh（-）的患者差异具有统计学意义（p = 0.04）。
在本研究中，我们未发现HER2状态与ABO血型及Rh因子之间存在任何关联。然而，需要更多患者参与的进一步研究来确定血型在乳腺癌患者中的作用（如有）。
